Cargando…

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

BACKGROUND: Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads. METHODS: In this ongoing, double-blind, phase 1–3 trial involving nonhospitalized patients with Covid-19, we investigated two fully human, neutralizing monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinreich, David M., Sivapalasingam, Sumathi, Norton, Thomas, Ali, Shazia, Gao, Haitao, Bhore, Rafia, Musser, Bret J., Soo, Yuhwen, Rofail, Diana, Im, Joseph, Perry, Christina, Pan, Cynthia, Hosain, Romana, Mahmood, Adnan, Davis, John D., Turner, Kenneth C., Hooper, Andrea T., Hamilton, Jennifer D., Baum, Alina, Kyratsous, Christos A., Kim, Yunji, Cook, Amanda, Kampman, Wendy, Kohli, Anita, Sachdeva, Yessica, Graber, Ximena, Kowal, Bari, DiCioccio, Thomas, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781102/ https://www.ncbi.nlm.nih.gov/pubmed/33332778 http://dx.doi.org/10.1056/NEJMoa2035002

Ejemplares similares

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
por: Weinreich, David M., et al.
Publicado: (2021)

LB4. Casirivimab and Imdevimab for Treatment of Hospitalized Patients With COVID-19 Receiving Low Flow or No Supplemental Oxygen
por: Mylonakis, Eleftherios, et al.
Publicado: (2021)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus
por: Sivapalasingam, Sumathi, et al.
Publicado: (2021)

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial
por: Portal-Celhay, Cynthia, et al.
Publicado: (2022)

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial
por: Sivapalasingam, Sumathi, et al.
Publicado: (2022)

A drug‐disease model for predicting survival in an Ebola outbreak
por: Toroghi, Masood Khaksar, et al.
Publicado: (2022)

COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes
por: O'Brien, Meagan P., et al.
Publicado: (2021)

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
por: O’Brien, Meagan P., et al.
Publicado: (2021)

Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention
por: O’Brien, Meagan P., et al.
Publicado: (2021)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
por: Isa, Flonza, et al.
Publicado: (2022)

Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
por: O’Brien, Meagan P., et al.
Publicado: (2021)

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
por: Baum, Alina, et al.
Publicado: (2020)

Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
por: Arikawa, Shigehisa, et al.
Publicado: (2022)

Compassionate Use of REGEN-COV(®) in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders
por: Stein, David, et al.
Publicado: (2021)

REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan
por: Sakurai, Ayana, et al.
Publicado: (2022)

REGN-EB3: First Approval
por: Markham, Anthony
Publicado: (2021)

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
por: Simões, Eric A F, et al.
Publicado: (2020)

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
por: Herman, Gary A, et al.
Publicado: (2022)

Le régne de l'esprit malin
por: Ramuz, C. F. (Charles Ferdinand), 1878-1947
Publicado: (1946)

High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV
por: Sasaki, Hiroaki, et al.
Publicado: (2022)

Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability
por: Nguyen, Hung, et al.
Publicado: (2022)

Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies
por: Rofail, Diana, et al.
Publicado: (2022)

Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients
por: Rofail, Diana, et al.
Publicado: (2022)

Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial
por: Boyapati, Anita, et al.
Publicado: (2021)

REGEN-COV(®) antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification
por: Irvin, Susan C, et al.
Publicado: (2021)

Reliability and Validity of an Instrument of COVID-19 Patient-Reported Symptoms in Outpatients
por: Rofail, Diana, et al.
Publicado: (2022)

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
por: Hansen, Johanna, et al.
Publicado: (2020)

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
por: Baum, Alina, et al.
Publicado: (2020)

Un « @-CPLF » sous le règne de la COVID-19
por: Schlemmer, F.
Publicado: (2021)

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
por: Hooper, Andrea T., et al.
Publicado: (2022)

RegnANN: Reverse Engineering Gene Networks Using Artificial Neural Networks
por: Grimaldi, Marco, et al.
Publicado: (2011)

Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
por: Kurshan, Ashwini, et al.
Publicado: (2023)

Histoire populaire du règne de Léopold 1er roi des Belges
por: Hymans, Louis Salomon, 1829-1884
Publicado: (1865)

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
por: Copin, Richard, et al.
Publicado: (2021)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021)

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Novel genetic variants in miR-191 gene and familial ovarian cancer
por: Shen, Jie, et al.
Publicado: (2010)

Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity
por: Nguyen, Hanna, et al.
Publicado: (2021)

S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lee, Hans C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lg9tfkggguvi8d50fgt55aaeai